- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AstraZeneca PLC ADR (AZN)
"AstraZeneca PLC ADR stock price live, this page displays NASDAQ AZN stock exchange data. View the AZN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AstraZeneca PLC ADR real time stock price chart below.
What Is the AstraZeneca PLC ADR Stock Price Today?
The AstraZeneca PLC ADR stock price today is 71.99.
What Is the Stock Symbol for AstraZeneca PLC ADR?
The stock symbol for AstraZeneca PLC ADR is ""AZN.""
What Stock Exchange Does AstraZeneca PLC ADR Trade On?
AstraZeneca PLC ADR is listed and trades on the NASDAQ stock exchange.
Is AstraZeneca PLC ADR a Good Stock to Buy?
Determining whether AstraZeneca PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AZN quote. (ISIN: US0463531089)"
What Is the AstraZeneca PLC ADR Stock Price Today?
The AstraZeneca PLC ADR stock price today is 71.99.
What Is the Stock Symbol for AstraZeneca PLC ADR?
The stock symbol for AstraZeneca PLC ADR is ""AZN.""
What Stock Exchange Does AstraZeneca PLC ADR Trade On?
AstraZeneca PLC ADR is listed and trades on the NASDAQ stock exchange.
Is AstraZeneca PLC ADR a Good Stock to Buy?
Determining whether AstraZeneca PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AZN quote. (ISIN: US0463531089)"
NASDAQ
Currency in USD
71.99
-0.37(-0.51%)
Closed
Pre Market
72.18+0.19(+0.26%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
71.78
72.70
52 wk Range
60.47
87.68
AZN Scorecard
Full Analysis
Trading at a high earnings multiple
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
71.7872.70
52 wk Range
60.4787.68
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.11%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AZN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
85.34
Upside
+18.55%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
- AstraZeneca's Full Year and Q4 2024 results
- Investing.com
- AstraZeneca's Full Year and Q4 2024 results
- Investing.com
AstraZeneca PLC ADR Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC ADR SWOT Analysis
Oncology Powerhouse | AstraZeneca's robust oncology portfolio and pipeline drive growth, with key drugs like Enhertu and Imfinzi showing promising results in various cancer treatments |
Financial Strength | Raised guidance for 2024 reflects confidence, with total revenue and core earnings expected to grow in mid-teens percentage at constant exchange rates |
Strategic Expansion | Explore AstraZeneca's moves into earlier treatment lines and new therapeutic modalities, including antibody-drug conjugates and CAR-T cell therapies |
Market Valuation | Analysts set price targets ranging from $82 to $89, with AstraZeneca appearing undervalued based on InvestingPro's Fair Value analysis |
Compare AZN to Peers and Sector
Metrics to compare | AZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.6x | 15.1x | −0.6x | |
PEG Ratio | 1.75 | 0.03 | 0.00 | |
Price/Book | 5.4x | 3.6x | 2.6x | |
Price / LTM Sales | 4.1x | 2.4x | 3.1x | |
Upside (Analyst Target) | 20.9% | 42.1% | 48.2% | |
Fair Value Upside | Unlock | 33.1% | 8.0% | Unlock |
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 85.34
(+18.55% Upside)
Earnings
Latest Release
Feb 06, 2025
EPS / Forecast
2.09 / 1.06
Revenue / Forecast
14.89B / 14.15B
People Also Watch
FAQ
What Is the AstraZeneca ADR (AZN) Stock Price Today?
The AstraZeneca ADR stock price today is 71.99
What Stock Exchange Does AstraZeneca ADR Trade On?
AstraZeneca ADR is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for AstraZeneca ADR?
The stock symbol for AstraZeneca ADR is "AZN."
Does AstraZeneca ADR Pay Dividends? What’s The Current Dividend Yield?
The AstraZeneca ADR dividend yield is 2.11%.
What Is the AstraZeneca ADR Market Cap?
As of today, AstraZeneca ADR market cap is 223.22B.
What is AstraZeneca ADR Earnings Per Share?
The AstraZeneca ADR EPS is 4.54.
What Is the Next AstraZeneca ADR Earnings Date?
AstraZeneca ADR will release its next earnings report on Apr 28, 2025.
From a Technical Analysis Perspective, Is AZN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.